Detalhe da pesquisa
1.
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.
J Clin Oncol
; 41(23): 3881-3890, 2023 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37549482
2.
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.
Ann Oncol
; 23(2): 406-10, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21543626
3.
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
Br J Cancer
; 98(11): 1753-8, 2008 Jun 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-18506177
4.
Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.
Ann Oncol
; 22(4): 988-990, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21321087
5.
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
Ann Oncol
; 17 Suppl 5: v118-22, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16807438
6.
Stage IB malignant thymoma in a Lynch syndrome patient with multiple cancers: response to incidental administration of oxaliplatin and 5-fluorouracil.
J Chemother
; 18(4): 433-6, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17024802
7.
Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
J Natl Cancer Inst
; 86(21): 1608-17, 1994 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-7932825
8.
Association of cyst type with risk factors for breast cancer and relapse rate in women with gross cystic disease of the breast.
Cancer Res
; 52(7): 1791-5, 1992 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-1551110
9.
Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Endocr Relat Cancer
; 12(1): 109-17, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15788643
10.
Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.
Endocr Relat Cancer
; 12(2): 383-92, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15947110
11.
Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines.
J Clin Oncol
; 18(19): 3370-7, 2000 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-11013277
12.
Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
J Clin Oncol
; 14(4): 1165-72, 1996 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-8648371
13.
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
J Clin Oncol
; 18(17): 3068-77, 2000 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-11001674
14.
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
J Clin Oncol
; 15(1): 297-303, 1997 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-8996156
15.
Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study.
Int J Biol Markers
; 20(3): 156-68, 2005.
Artigo
em Inglês
| MEDLINE | ID: mdl-16240843
16.
p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Clin Cancer Res
; 6(7): 2751-8, 2000 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-10914720
17.
Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.
J Clin Endocrinol Metab
; 85(6): 2234-8, 2000 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-10852456
18.
Activity and safety of a prolonged daily schedule of zoledronic acid in a patient with bone metastases from urothelial carcinoma.
Ann Oncol
; 20(2): 389-90, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19153111
19.
Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen.
Ann Oncol
; 20(12): 2019-20, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19770205
20.
Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease.
Eur J Cancer
; 30A(14): 2082-4, 1994.
Artigo
em Inglês
| MEDLINE | ID: mdl-7857707